Haemoctin (Human Coagulation Factor Viii)

Haemoctin is indicated for the management of bleeding disorders related to factor VIII deficiency.

• Treatment of bleeding episodes in patients with congenital hemophilia A.
• Routine prophylaxis to prevent spontaneous joint and muscle bleeds in hemophilia A.
• Management of peri‑operative hemostasis for surgical procedures in hemophilia A patients.
• Control of bleeding in acquired hemophilia A associated with autoantibodies.
• Adjunct therapy for patients undergoing invasive dental or minor surgical interventions.

The safety profile of Haemoctin reflects the typical reactions observed with factor VIII replacement products.

Common

• Mild headache or fatigue.
• Low‑grade fever.
• Localized injection site erythema or swelling.
• Transient increase in liver enzymes.
• Nausea or mild abdominal discomfort.

Serious

• Development of inhibitors (neutralizing antibodies) to factor VIII.
• Anaphylactic or severe allergic reactions.
• Thromboembolic events, including deep‑vein thrombosis.
• Disseminated intravascular coagulation (rare).
• Severe hemolysis or renal impairment.

Clinicians should consider several precautions when prescribing Haemoctin.

• Assess for a history of inhibitors to factor VIII before initiating therapy.
• Monitor for signs of allergic reaction, especially during the first infusion.
• Use caution in patients with a history of thrombotic events or cardiovascular disease.
• Evaluate liver and renal function periodically during long‑term treatment.
• Avoid concurrent use with other pro‑coagulant agents unless medically justified.
• Educate patients on proper storage and handling of the injectable solution.

Potential drug interactions with Haemoctin should be reviewed before treatment.

Avoid

• Concurrent administration of high‑dose activated pro‑thrombin complex concentrates, which may increase thrombotic risk.
• Use of antifibrinolytic agents (e.g., tranexamic acid) without medical supervision in patients with known inhibitors.

Use with caution

• Immunosuppressive therapies that could affect inhibitor development.
• Concomitant use of other clotting factor concentrates.
• Medications that alter hepatic metabolism, such as certain antivirals.
• Vaccines administered intramuscularly, which may increase bleeding risk at the injection site.